Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Gema Perez"'
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/a9a8996edca849559e3286979818e7ad
RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer
Autor:
Marina Ciscar, Eva M Trinidad, Gema Perez‐Chacon, Mansour Alsaleem, Maria Jimenez, Maria J Jimenez‐Santos, Hector Perez‐Montoyo, Adrian Sanz‐Moreno, Andrea Vethencourt, Michael Toss, Anna Petit, Maria T Soler‐Monso, Victor Lopez, Jorge Gomez‐Miragaya, Clara Gomez‐Aleza, Lacey E Dobrolecki, Michael T Lewis, Alejandra Bruna, Silvana Mouron, Miguel Quintela‐Fandino, Fatima Al‐Shahrour, Antonio Martinez‐Aranda, Angels Sierra, Andrew R Green, Emad Rakha, Eva Gonzalez‐Suarez
Publikováno v:
EMBO Molecular Medicine, Vol 15, Iss 4, Pp 1-12 (2023)
Abstract Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL p
Externí odkaz:
https://doaj.org/article/1a7e932a6a184ce6a384d4a58e43a0be
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Externí odkaz:
https://doaj.org/article/e9a37a371d884f22af5eb2915d385379
Autor:
Gema Perez-Chacon, Juan M. Zapata
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) is a heterogeneous disease consisting of at least two separate subtypes, based on the mutation status of the immunoglobulin heavy chain variable gene (IGHV) sequence. Exposure to ant
Externí odkaz:
https://doaj.org/article/6f46f922fd494cd893072f8ab16ca20c
Autor:
Marta Compte, Seandean L. Harwood, Jorge Martínez-Torrecuadrada, Gema Perez-Chacon, Patricia González-García, Antonio Tapia-Galisteo, Paul M. P. Van Bergen en Henegouwen, Aránzazu Sánchez, Isabel Fabregat, Laura Sanz, Juan M. Zapata, Luis Alvarez-Vallina
Publikováno v:
Frontiers in Immunology, Vol 11 (2021)
Agonistic monoclonal antibodies (mAbs) targeting the co-stimulatory receptor 4-1BB are among the most effective immunotherapeutic agents across pre-clinical cancer models. However, clinical development of full-length 4-1BB agonistic mAbs, has been ha
Externí odkaz:
https://doaj.org/article/73fed565702c4bd49e60af922d155683
Autor:
Marta Compte, Seandean Lykke Harwood, Ines G. Muñoz, Rocio Navarro, Manuela Zonca, Gema Perez-Chacon, Ainhoa Erce-Llamazares, Nekane Merino, Antonio Tapia-Galisteo, Angel M. Cuesta, Kasper Mikkelsen, Eduardo Caleiras, Natalia Nuñez-Prado, M. Angela Aznar, Simon Lykkemark, Jorge Martínez-Torrecuadrada, Ignacio Melero, Francisco J. Blanco, Jorge Bernardino de la Serna, Juan M. Zapata, Laura Sanz, Luis Alvarez-Vallina
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Cancer therapy using systemically administrated 4-1BB-targeting antibodies is often associated with severe toxicity due to the nonspecific activation of autoreactive T cells. Here, the authors have developed a trimeric antibody targeting both 4-1BB a
Externí odkaz:
https://doaj.org/article/7575acc4586f44568954b0510de1f6d3
Autor:
Gema Perez-Chacon, Magdalena Adrados, Maria T. Vallejo-Cremades, Sophie Lefebvre, John C. Reed, Juan M. Zapata
Publikováno v:
Frontiers in Immunology, Vol 9 (2019)
TNF-Receptor Associated Factor (TRAF)-3 is a master regulator of B cell homeostasis and function. TRAF3 has been shown to bind and regulate various proteins involved in the control of innate and adaptive immune responses. Previous studies showed that
Externí odkaz:
https://doaj.org/article/413020fb91544a7b95486d368cc259b4
Autor:
Juan M. Zapata, Gema Perez-Chacon, Pablo Carr-Baena, Ivan Martinez-Forero, Arantza Azpilikueta, Itziar Otano, Ignacio Melero
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
CD137 (4-1BB, Tnsfr9) is a member of the TNF-receptor (TNFR) superfamily without known intrinsic enzymatic activity in its cytoplasmic domain. Hence, akin to other members of the TNFR family, it relies on the TNFR-Associated-Factor (TRAF) family of a
Externí odkaz:
https://doaj.org/article/127bac55c5674396941411282c423325
Autor:
Nerea Rebolleda, Ignacio Losada-Fernandez, Gema Perez-Chacon, Raquel Castejon, Silvia Rosado, Marta Morado, Maria Teresa Vallejo-Cremades, Andrea Martinez, Juan A Vargas-Nuñez, Paloma Perez-Aciego
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0154159 (2016)
B-cell chronic lymphocytic leukemia (CLL) remains an incurable disease, and despite the improvement achieved by therapeutic regimes developed over the last years still a subset of patients face a rather poor prognosis and will eventually relapse and
Externí odkaz:
https://doaj.org/article/16e45890b96e4eb488e5dcc432876f07
Autor:
Abel, Arroyo, Erna, Alberts, Berger Mette, M., Guillaume, Besch, Costel, Besançon Bodolea, Michael, Casaer, Pérez, Cheng Meisy, Jean-Michel, Constantin, Swarna, Deepak, de Man Angelique, M.E., Frantisek, Duska, Patricia, Fodor, Kristina, Fuest, Thierry, Fumeaux, Hubert, Grand, Gundogan, K., Jan, Gunst, Mohan, Gurjar, Laurent, Heyer, Shihan, Huq, Carole, Ichai, Motiul, Islam, Samir, Jaber, Nikilesh, Jain, Matthieu, Jamme, Ib, Jammer, Olivier, Joannes-Boyau, Veronika, Jung, Inga, Karu, Kamal Habeeb, Keryakos Hesham, Gian-Reto, Kleger, Tim, Krol, Friedrich, Kuhn Karl, Marcus, Laube, Yoann, Launey, Manu, Malbrain, Manrique Ezequiel, Julien, Marrel, Roberto, Martinez-Alejos, Mongardon, Nicolas, Conway, Morris Andrew, Madhu, Pahuja, Fernando, Pereira, Gema, Pérez, Marie-Helene, Perez, Carmen, Pfortmuller, Annika, Reintam Blaser, Ricardo, Rosenfeld, Noryani, Samat, Schaller Stefan, J., Shannon, Simpson, Kelly, Straka, Tamas, Szakmany, Kadri, Tamme, Arthur, Van Zanten, Verçoza, Viana Marina, Berger, M.M., Appelberg, O., Reintam-Blaser, A., Ichai, C., Joannes-Boyau, O., Casaer, M., Schaller, S.J., Gunst, J., Starkopf, J.
Publikováno v:
In Clinical Nutrition May 2021 40(5):3615-3621